Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 3, 2012, Pages 788-798

  Romero, Elba ^a   Veĺez De Mendizabal, Nieves ^a   Cendrós, Josep María ^b   Peraire, Concepción ^b   Bascompta, Emma ^b   Obach, Rosendo ^b   Troćoniz, Iñaki F ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG RECEPTOR; TESTOSTERONE; TRIPTORELIN;

ADULT; AGED; ARTICLE; COMPETITIVE INHIBITION; COMPUTER PROGRAM; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS; RECEPTOR BINDING; SUSTAINED RELEASE FORMULATION; TESTOSTERONE BLOOD LEVEL; VOLUNTEER;

ADOLESCENT; ANTINEOPLASTIC AGENTS, HORMONAL; CASE-CONTROL STUDIES; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DOWN-REGULATION; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MODELS, BIOLOGICAL; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TESTOSTERONE; TRIPTORELIN PAMOATE;

EID: 84865176055     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.195560     Document Type: Article

References (16)

1. Ariuens EJ and Simonis AM (1964) A molecular basis for drug action. The interaction of one or more drugs with different receptors. J Pharm Pharmacol 16:289-312.
2. Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481-504.
3. Beal SL and Sheiner LB (2006) NONMEM Users Guide. Icon Development Solutions, Ellicott City, MD.
4. Fattinger KE, Verotta D, Porchet HC, Munafo A, Le Cotonnec JY, and Sheiner LB (1996) Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. Am J Physiol Endocrinol Metab 271:E775-E787.
5. Gries JM, Munafo A, Porchet HC, and Verotta D (1999) Down-regulation models and modeling of testosterone production induced by recombinant human choriogonadotropin. J Pharmacol Exp Ther 289:371-377. (Pubitemid 29156051)
6. Holford NH, Ambros RJ, and Stoeckel K (1992) Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. J Pharmacokinet Biopharm 20:421-442. (Pubitemid 23034408)
7. Jemal A, Siegel R, Ward E, Hao Y, Xu J, and Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin CA 50:225-249.
8. Kiesel LA, Rody A, Greb RR, and Szilágyi A (2002) Clinical use of GnRH analogues. Clin Endocrinol (Oxf) 56:677-687. (Pubitemid 34785898)
9. Labrie F (2010) Hormonal therapy of prostate cancer. Prog Brain Res 182:321-341.
10. Lindbom L, Ribbing J, and Jonsson EN (2004) Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75:85-94. (Pubitemid 38798039)
11. Ludden TM, Beal SL, and Sheiner LB (1994) Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm 22:431-445.
12. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, et al. (2011) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59:572-583.
13. Müller FO, Terblanchè J, Schall R, van Zyl Smit R, Tucker T, Marais K, Groenewoud G, Porchet HC, Weiner M, and Hawarden D (1997) Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. Br J Clin Pharmacol 44:335-341. (Pubitemid 27402107)
14. Pechstein B, Nagaraja NV, Hermann R, Romeis P, Locher M, and Derendorf H (2000) Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers. J Clin Pharmacol 40:266-274.
15. Savic RM, Jonker DM, Kerbusch T, and Karlsson MO (2007) Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34:711-726. (Pubitemid 47477040)
16. Tornøe CW, Agersø H, Senderovitz T, Nielsen HA, Madsen H, Karlsson MO, and Jonsson EN (2007) Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues. Br J Clin Pharmacol 63:648-664. (Pubitemid 46753566)